Gene Therapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Researchers from University of Torino, Institute for Cancer Research and Treatment discuss findings in cancer gene therapy
May 10th, 2007
New investigation results, "The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo," are detailed in a study published in Clinical Cancer Research. "Advanced ovarian cancers are initially responsive to combinatorial chemotherapy with platinum drugs and taxanes but, in most cases, develop drug resistance. We recently showed that, in vitro, hepatocyte growth factor (HGF) enhances death of human ovarian cancer cell lines treated with cisplatin (CDDP) and paclitaxel," investigators in Candiolo, Italy report. "The present study addresses whether in vivo HGF makes ovarian carcinoma cells more...
Source: Gene Therapy Weekly (2007-05-10)
|
